Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury

Condition:   Spinal Cord Injury Interventions:   Biological: MT-3921 Low dose;   Biological: MT-3921 High dose Sponsor:   Mitsubishi Tanabe Pharma Development America, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials